5 things to know about CRISPR and gene editing in the COVID era
Precision medicine is playing a key role in understanding COVID-19. Here's how gene testing and gene editing are accelerating the future of healthcare.
Mammoth Biosciences is harnessing the diversity of nature to power the next generation of CRISPR products. Through the discovery and development of novel CRISPR systems, the company is enabling the full potential of its platform to read and write the code of life. By leveraging its internal research and development and exclusive licensing to patents, Mammoth Biosciences provides enhanced diagnostics and genome editing for life science research, healthcare, agriculture, biodefense and more. Based in Brisbane, California, Mammoth Biosciences is backed by institutional investors including Redmile Group, Foresite Capital, Senator Investment Group, Sixth Street, Decheng, Mayfield, NFX, and 8VC.